Posted by Michael Wonder on 24 Oct 2022
Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer
24 October 2022 - Approval based on HIMALAYA Phase 3 trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% versus sorafenib.
AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma, the most common type of liver cancer.
